Pay in 4 interest-free payments of $6.08 Learn more
Ships within 48 hours · Estimated delivery Oct 11 - Oct 16
In the gastrointestinal system, they slow gastric emptying and reduce appetite, contributing to weight loss
Presented for research literature review only Guarnieri G et al
In vitro IC 50 value of mGIPR-Ab could then be used to compare with exposure levels in brain, plasma, and peripheral tissues following central or systemic administration of mGIPR-Ab in diet-induced obese male mice
The discovery of GLP-1R/GcgR dual agonists has provided a fresh medicinal approach and renewed hope that obesity and its associated abnormalities might be managed with medicines as opposed to surgical interventions
In September 2025, the WHO added several GLP-1 drugs, including semaglutide and tirzepatide, to its Model List of Essential Medicines to improve global access to therapies used for diabetes and obesity-related conditions
US$ 26.91
US$ 22.20
US$ 28.01
